Insights into the binding modes of human β 3-adrenergic receptor agonists with ligand-based and receptor-based methods

Molecular Diversity

Volumn 15, Issue 4, 2011, Pages 817-831

  Jin, Fangfang ^a   Lu, Chunhua ^a   Sun, Xianqiang ^a   Li, Weihua ^a   Liu, Guixia ^a   Tang, Yun ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Adrenergic receptor; 3 Adrenergic receptor agonist; Holomogy modeling; Molecular docking; Pharmacophore modeling

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; L 796568; LY 377604; SOLABEGRON; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-3; REPRODUCIBILITY OF RESULTS; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; USER-COMPUTER INTERFACE;

EID: 84855233264     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-011-9311-8     Document Type: Article

References (54)

1. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597-598. doi:10.1038/214597a0
2. Arch JRS, Kaumann KAJ (1993) β 3 and atypical β-adrenoceptors. Med Res Rev 13:663-729. doi:10.1002/med.2610130604 (Pubitemid 23319505)
3. 3-adrenergic receptor. Science 24:1118-1121. doi:10.1126/science.2570461 (Pubitemid 19231821)
4. Lelias JM, KaghadM, RodriguezM, Chalon P, Bonnin J, Dupre I, Delpech B, BensaidM, LeFur G, Ferrara P, CaputD (1993) Molecular cloning of a human β 3-adrenergic receptor cDNA. FEBS Lett 324:127-130. doi:10.1016/0014-5793(93) 81377-C (Pubitemid 23170399)
5. 3-adrenergic receptor. Mol Pharmacol 40:895-899
6. 3-adrenoceptor. Br J Pharmacol 112:911-919 (Pubitemid 24199103)
7. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molonoff PB, Ruffolo RRJ, Trendelenburg U (1994) International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136
8. Muzzin P, Revelli JP, Kuhne F, Gocayne JD, McCombie WR, Venter JC,Giacobino JP, Fraser CM (1991) An adipose tissue-specific β-adrenergic receptor. Molecular cloning and down-regulation in obesity. J Biol Chem 266:24053-24058 (Pubitemid 21908904)
9. Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE,WilsonCWS (1984) Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309:163-165.doi:10.1038/309163a0 (Pubitemid 14142787)
10. Kordik CP, Reitz AB (1999) Pharmacological treatment of obesity: Therapeutic strategies. J Med Chem 42:181-201. doi:10.1021/jm980521l (Pubitemid 29069852)
11. 3-adrenoceptor polymorphism with obesity and diabetes: current status. Trends Pharmacol Sci 18:449-454. doi:10.1126/science.18.458.449
12. 3- adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21:426-431. doi:10.1016/S0165-6147(00)01562-5
13. 3-adrenoceptor in the rat. Br J Pharmacol 118:2085-2098 (Pubitemid 26292581)
14. Berkowitz DE, Nardone NA, Smiley RM, Price DT, Kreutter DK, Fremeau RTS (1995) Distribution of beta 3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 289:223-228. doi:10.1016/0922-4106(95)90098-5
15. 3-adrenoceptor- mediated effect. Eur J Pharmacol 353:281-287. doi:10.1016/S0014-2999(98)00419-1 (Pubitemid 28352275)
16. 3-adrenoceptors in the guinea pig common bile duct and colon. Pharmacology 51:288-297
17. Tomiyama Y, Hayakawa K, ShinagawaK,Akahane M, AjisawaY, Park Y-C (1998) β-adrenoceptor subtypes in the ureteral smooth muscle of rats, rabbits and dogs. Eur J Pharmacol 352:269-278. doi:10.1016/S0014-2999(98)00360-4 (Pubitemid 28345127)
18. Imanishi M, Tomishima Y, Itou S, Hamashima H, Nakajima Y, Washizuka K, Sakurai M, Matsui S, Imamura E, Ueshima K, Yamamoto T, Yamamoto N, Ishikawa H, Nakano K, Unami N, Hamada K, Matsumura Y, Takamura F, Hattori K (2008) Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta(3)-adrenergic receptor agonists with good oral bioavailability. Part I. J Med Chem 51:1925-1944.doi:10.1021/jm701324c (Pubitemid 351438874)
19. Prathipati P, Saxena AK (2005) Characterization of beta(3)-adrenergic receptor: determination of pharmacophore and 3D QSAR model for beta(3) adrenergic receptor agonism. J Comput Aided Mol Des 19:93-110. doi:10.1007/s10822-005-1558-7 (Pubitemid 40974010)
20. Ahmed M, Ishiguro M, Nagatomo T (2006) Molecular modeling of SWR-0342SA, a beta(3)-selective agonist, with beta(1)- and beta(3)-adrenoceptor. Life Sci 78:2019-2023. doi:10.1016/j.lfs.2005.09.023
21. Shakya N, Roy KK, Saxena AK (2009) Substituted 1,2,3,4- tetrahydroquinolin- 6-yloxypropanes as beta(3)-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling. Bioorg Med Chem 17:830-847. doi:10.1016/j.bmc.2008.11.030
22. Maruyama T, Seki N, Onda K, Suzuki T, Kawazoe S,HayakawaM (2009) Discovery of novel thiourea derivatives as potent and selective beta 3-adrenergic receptor agonists. Bioorg Med Chem 17:5510-5519. doi:10.1016/j.bmc.2009.06.031
23. Mizuno K, Seki M, Harada H, Taoka I, Yamashita H, Oue M (2005) Discovery of 1,7-cyclized indoles as a new class of potent and highly selective human beta(3)-adrenergic receptor agonists with high cell permeability. BioorgMed Chem 13:855-868. doi:10.1016/j.bmc.2004.10.032 (Pubitemid 40093626)
24. Mizuno K, Sawa M, Harada H, Tateishi H, Oue M, Tsujiuchi H (2004) Tryptamine-based human beta(3)-adrenergic receptor agonists. Part 1:SARstudies of the 7-position of the indole ring. Bioorg Med Chem Lett 14:5959-5962. doi:10.1016/j.bmcl.2004.10.035 (Pubitemid 39531250)
25. Stevens FC, Bloomquist WE, Borel AG, Cohen ML, Droste CA, Heiman ML (2007) Potent oxindole based human beta(3) adrenergic receptor agonists. Bioorg Med Chem Lett 17:6270-6273. doi:10.1016/j.bmcl.2007.09.011 (Pubitemid 47554689)
26. Finley DR, Bell MG, Borel AG, Bloomquist WE, Cohen ML, HeimanML (2006) Potent benzimidazolone based human beta(3)-adrenergic receptor agonists. Bioorg Med Chem Lett 16:5691-5694. doi:10.1016/j.bmcl.2006.08.010 (Pubitemid 44415432)
27. Hattori K, Toda S, Imanishi M, Itou S, Nakajima Y, Washizuka K (2009) Discovery of highly potent and selective biphenylacylsulfonamide-based beta(3)-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: Part 5. J Med Chem 52:3063-3072. doi:10.1021/jm9000709
28. Lafontaine JA, Day RF, Dibrino J, Hadcock JR, Hargrove DM, Linhares M (2007) Discovery of potent and orally bioavailable heterocycle-based beta(3)-adrenergic receptor agonists, potential therapeutics for the treatment of obesity. Bioorg Med Chem Lett 17:5245-5250. doi:10.1016/j.bmcl.2007.06.072 (Pubitemid 47259644)
29. Maruyama T, Onda K, Hayakawa M, Matsui T, Takasu T, Ohta M (2009) Discovery of novel acetanilide derivatives as potent and selective beta 3-adrenergic receptor agonists. Eur J Med Chem 44:2533-2543. doi:10.1016/j.ejmech.2009.01.022
30. Imanishi M, Itou S, Washizuka K, Hamashima H, Nakajima Y, Araki T (2008) Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta 3 adrenergic receptor agonistswith good oral bioavailability. Part II. JMed Chem 51:4002-4020. doi:10.1021/jm8000345 (Pubitemid 351956528)
31. Imanishi M, Nakajima Y, Tomishima Y, Hamashima H, Washizuka K, SakuraiM (2008) Discovery of a novel series of benzoic acid derivatives as potent and selective human beta(3) adrenergic receptor agonistswith good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ethermoiety. JMed Chem 51:4804-4822. doi:10.1021/jm800222k
32. CATALYST, 4.10. Accelrys Inc. http://www.accelrys.com. San Diego, CA
33. 3- adrenoceptor transmembrane residues involved in ligand binding and signal transduction. Eur J Biochem 251:590-596 (Pubitemid 28108951)
34. Sum FW, Wong V, Han S, Largis E, Mulvey R, Tillett J (2003) Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists. Bioorg Med Chem Lett 13:2191-2194. doi:10.1016/S0960-894X(03)00387-1 (Pubitemid 36694302)
35. Goble SD, Wang LP, Howell KL, Bansal A, Berger R, Brockunier L (2010) Heterocyclic acetamide and benzamide derivatives as potent and selective beta(3)-adrenergic receptor agonists with improved rodent pharmacokinetic profiles. BioorgMed Chem Lett 20:1895-1899. doi:10.1016/j.bmcl.2010.01.130
36. Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S (2005) Tryptamine-based human beta 3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. Bioorg Med Chem Lett 15:1061-1064. doi:10.1016/j.bmcl.2004.12.033 (Pubitemid 40458648)
37. Maruyama T, Onda K, Hayakawa M, Seki N, Takahashi T, Moritomo H (2009) Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta 3-adrenergic receptor agonists. Bioorg Med Chem 17:3283-3294. doi:10.1016/j.bmc.2009.03.044
38. Maruyama T, Onda K, Hayakawa M, Suzuki T, Kimizuka T, Matsui T (2010) Synthesis and evaluation of novel phenylethanolamine derivatives containing acetanilides as potent and selective beta 3-adrenergic receptor agonists. Chem Pharm Bull 58:533-545
39. Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF (2000) Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-4-2-2-hydroxy-2-(3-pyridinyl)ethyl amino ethyl phenyl -4-4-4 -(trifluoromethyl)phenyl thiazol-2-yl benzenesulfonamide. J Med Chem 43:3832-3836.doi:10.1021/jm000286i
40. Prime, 2.0 (2008) Schrödinger, LLC. http://www.schrodinger.com.New York, NY
41. Oliveira L, Paiva ACM, Vriend G (1993) A common motif in Gprotein-coupled 7 transmembrane helix receptors. J Comput Aided Mol Des 7:649-658. doi:10.1007/BF00125323
42. 3- adrenergic receptor. Annu Rev Pharmacool Toxicol 37:421-450
43. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM (1992) Stereochemical quality of protein structure coordinates. Proteins 12:345-364. doi:10.1002/prot.340120407
44. Discover studio 2.1,Accelrys Inc. http://accelrys.com/. San Diego,CA, USA
45. Virtual ScreeningWorkflow(2008) Schrödinger, LLC. http://www.schrodinger.com. New York, NY
46. Brockunier LL, Candelore MR, CascieriMA, LiuY, Tota L,Wyvratt MJ, Fisher MH, Weber AE, Parmee ER (2001) Human beta(3) adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties. BioorgMed Chem Lett 11:379-382.doi:10.1016/S0960-894X(00)00669-7 (Pubitemid 32115851)
47. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC (2007) High-resolution crystal structure of an engineered human beta(2)-adrenergic G protein-coupled receptor. Science 318:1258-1265. doi:10.1126/science.1150577 (Pubitemid 350172884)
48. Furse KE, Lybrand TP (2003) Three-dimensional models for betaadrenergic receptor complexes with agonists and antagonists. J Med Chem 46:4450-4462. doi:10.1021/jm0301437 (Pubitemid 37238747)
49. Hillisch A, Pineda LF, Hilgenfeld R (2004) Utility of homology models in the drug discovery process. Drug Discov Today 9:659-669. doi:10.1016/S1359- 6446(04)03196-4 (Pubitemid 38981720)
50. Costanzi S (2008) On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta(2)-adrenergic receptor. J Med Chem 51:2907-2914. doi:10.1021/jm800044k (Pubitemid 351706019)
51. Nikiforovich GV, Marshall GR, Baranski TJ (2008) Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor. Biochemistry 47:3117-3130. doi:10.1021/bi702321a (Pubitemid 351364905)
52. SlusarzMJ, Sikorska E, Slusarz R, Ciarkowski J (2006) Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor- bound conformations and interactions with vasopressin and oxytocin receptors. J Med Chem 49:2463-2469. doi:10.1021/jm051075m
53. Gigłdon A, Kazmierkiewicz R, Slusarz R, Pasenkiewicz-Gierula M, Ciarkowski J (2003) Molecular dynamics study of 4-OHphenylacetyl-D-Y(Me)FQNRPR- NH2 selectivity to V1a receptor. J Mol Model 9:372-378. doi:10.1007/s00894-003- 0142-0 (Pubitemid 38097525)
54. Ballesteros JA, Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci 25:366-428. doi:10.1016/S1043-9471(05)80049-7